Skip to main content
Medica logo

Medica — Investor Relations & Filings

Ticker · MDC ISIN · IT0005460149 LEI · 815600FE16FA9F3E2296 XMIL Manufacturing
Open in API
Filings indexed 114 across all filing types
Latest filing 2022-12-16 Report Publication Anno…
Country IT Italy
Listing XMIL MDC

About Medica

https://www.medica.it/

Medica S.p.A. is a company specializing in advanced purification technologies. Its core business is the development and production of products for blood purification, with applications in dialysis, Continuous Renal Replacement Therapy (CRRT), and apheresis. The company's medical product portfolio includes polysulfone membranes, dialysis filters, hemofilters, and blood lines. It has expanded its expertise into other medical fields such as cardiology, oncology surgery, organ transplantation, urology, and gastroenterology. Leveraging its filtration know-how, Medica also operates a water purification division that produces hollow fiber membranes. Additionally, the company offers turnkey solutions for the biomedical sector, providing vertically integrated services from research and development to manufacturing, industrial automation, and regulatory management.

Recent filings

Filing Released Lang Actions
Medica SpA - Financial calendar 2023
Report Publication Announcement Classification · 95% confidence The document is explicitly titled 'Press Release' and its primary content is the announcement of the 'FINANCIAL CALENDAR 2023'. It lists future dates for the Board of Directors meetings to approve preliminary results, draft financial statements, and the Ordinary Shareholders' Meeting. This document is not the financial report itself (like 10-K or IR), nor is it a transcript or a detailed presentation. It is an announcement regarding the schedule for future corporate reporting events. This fits best under Report Publication Announcement (RPA), as it announces when reports will be published, or potentially Regulatory Filings (RNS) if RPA is too specific for a calendar announcement. Given the specific nature of announcing the schedule for financial report releases, RPA is the most appropriate fit, although RNS is a close fallback. Since the document is short and announces *when* reports will be released, RPA is chosen over classifying it as the actual report type.
2022-12-16 Italian
Medica SpA - Calendario finanziario 2023
Regulatory Filings Classification · 95% confidence The document is explicitly titled "Comunicato stampa" (Press Release) and its main content is the "CALENDARIO FINANZIARIO 2023" (Financial Calendar 2023). This calendar lists future dates for key corporate events, such as the presentation of preliminary results, board approvals of annual/half-year reports, and the Annual General Meeting (Assemblea ordinaria degli Azionisti). Since the document is an announcement *about* future reporting dates rather than the report itself (like 10-K, IR, or ER), and it is a general corporate announcement, it best fits the category for general regulatory announcements or filings that don't fit elsewhere. However, given the specific nature of announcing future financial events, it is often categorized as a general regulatory filing or an announcement related to investor relations. Since there is no specific code for a 'Financial Calendar Announcement', and it is not a Report Publication Announcement (RPA) which typically announces the *release* of an attached report, the most appropriate fallback is Regulatory Filings (RNS). It is a formal communication to the market regarding scheduled corporate actions.
2022-12-16 Italian
Medica - merger by incorporation of Slom in Tecnoideal
M&A Activity Classification · 95% confidence The document announces a specific corporate action: the 'MERGER BY INCORPORATION OF SLOM IN TECNOIDEAL' formalized on December 5, 2022. This type of event—a merger or acquisition—falls under the category of corporate transactions that affect the capital structure or ownership. Reviewing the definitions, 'M&A Activity (Code: TAR)' is defined as 'Announcements and documents related to merger proposals or takeover bids.' Although the merger is complete, the announcement details the finalization of a significant corporate transaction involving the incorporation of one entity into another, which aligns best with TAR. It is not a standard financial report (10-K, IR, ER) or a management/board change (MANG).
2022-12-05 Italian
Medica - Fusione per incorporazione di Slom in Tecnoideal
M&A Activity Classification · 95% confidence The document is a press release from Medica S.p.A. dated December 5, 2022, announcing the formal completion of a merger by incorporation (fusione per incorporazione) of Slom Srl into its subsidiary Tecnoideal Srl. This type of corporate action, involving a significant structural change (merger/acquisition), falls under the category of M&A Activity (TAR). Although it contains some general company profile and 2021 financial highlights, the primary purpose and headline focus is the completion of the transaction, which aligns best with the M&A Activity (TAR) definition, rather than a standard Earnings Release (ER) or Interim Report (IR). It is not a general regulatory filing (RNS) because it fits a more specific category.
2022-12-05 Italian
Medica acquires a patent from Exosomics
Regulatory Filings Classification · 100% confidence The document is a press release dated November 28, 2022, announcing that Medica S.p.A. has acquired a 50% share of a patent family from Exosomics S.p.A. This announcement details a specific corporate transaction (an acquisition related to intellectual property/patents) and provides company background and recent financial highlights (2021 results). This type of announcement, which is not a standard periodic financial report (10-K, IR, ER) but relates to corporate activity, best fits the category for M&A Activity (TAR) or potentially a general Regulatory Filing (RNS) if TAR is too specific for a patent purchase. Since the core event is the 'purchasing' of shares related to a patent, it strongly suggests a transaction or corporate action. Given the options, 'TAR' (M&A Activity) is the most appropriate fit for announcing the acquisition of a significant asset/patent stake, even if it's not a full takeover. If the transaction was purely financing or capital structure related, CAP would apply, but this is an asset acquisition. Since it is a specific corporate transaction announcement, TAR is chosen over the general RNS.
2022-11-28 English
Medica compra un brevetto da Exosomics
Regulatory Filings Classification · 99% confidence The document is a press release from Medica S.p.A. dated November 28, 2022, announcing the acquisition of a 50% stake in a patent family from Exosomics S.p.A. It details the strategic importance of the acquisition and provides a profile of the Medica Group, including its business segments and 2021 financial highlights. This type of announcement, focusing on a specific corporate transaction (M&A activity) and providing company background, is best classified as a general corporate announcement. Since there is no specific category for 'M&A Announcement' outside of 'TAR' (Merger Proposals/Takeover Bids), and this is a patent acquisition rather than a full merger/takeover, it falls under the general regulatory announcement category, 'RNS', as it is a material event disclosure that doesn't fit the other specific financial or reporting codes (like 10-K, ER, CAP, etc.). It is not a full report, nor is it a management discussion or earnings release.
2022-11-28 Italian

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.